Department of National Defence (DND) - *Africa *Foreign *Canada *Unspecified *Remote Offsite *Oceania *United States of America *Mexico *South America *World *Europe *Caribbean *North America *Central America *Asia *Aboriginal Lands, *National Capital Region (NCR), Ottawa, Ontario
The Department of National Defence (DND) is seeking a supplier for pralidoxime, intended to treat Canadian Armed Forces members who may have been exposed to chemical warfare agents. The initial requirement is for 450 doses, to be delivered before March 31, 2027. The procurement may also include an optional 600 doses, requested and delivered between April 1, 2027 and March 31, 2031. The tender is currently listed as open and closes November 10, 2026 at 2:00 p.m. The procurement is associated with Ottawa, Ontario, but the notice lists delivery or applicability across multiple locations, so the official documents should be reviewed for the precise delivery requirements. No security requirements are stated. Offers may be submitted in English or French. The notice indicates that participation is limited to Canadian suppliers and, where applicable, suppliers from eligible trading partners under reciprocal procurement rules. The Crown may negotiate with suppliers. Several tender documents and amendments are provided, including amendments 001, 002, and 003; businesses should review the latest version and confirm that all amendments are addressed before submitting an offer. This opportunity appears potentially relevant to businesses able to supply the specified pharmaceutical product and meet the tender’s technical, regulatory, delivery, and contracting requirements. The notice does not establish that any particular business qualifies. Verify the complete official tender notice and all attachments on Canada Buys before preparing or submitting a bid.
